Characteristics and clinical outcomes of breast cancer in young BRCA carriers according to tumor histology
Rattachement africain : be, it, fr, kr, il, nl, pl, in, us, au, ca, se, mx, lb, rs. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
BACKGROUND: Young women with breast cancer (BC) have an increased chance of carrying germline BRCA pathogenic variants (PVs). Limited data exist on the prognostic impact of tumor histology (i.e. ductal versus lobular) in hereditary breast cancer. METHODS: This multicenter retrospective cohort study included women aged ≤40 years with early-stage breast cancer diagnosed between January 2000 and December 2020 and known to carry germline PVs in BRCA1/2. Histology was locally assessed in each center. The Kaplan-Meier method and Cox regression analysis were used to assess disease-free survival and overall survival. RESULTS: Of 4628 patients included from 78 centers worldwide, 3969 (86%) had pure ductal, 135 (3%) pure lobular, and 524 (11%) other histologies. Compared with ductal tumors, lobular tumors were more often grade 1/2 (57.7% versus 22.1%), stage III (29.6% versus 18.5%), and luminal A-like (42.2% versus 12.2%). Lobular tumors were more often associated with BRCA2 PVs (71.1% BRCA2), while ductal tumors were more often associated with BRCA1 PVs (65.7% BRCA1). Patients with lobular tumors more often had mastectomy (68.9% versus 58.3%), and less often received chemotherapy (83.7% versus 92.9%). With a median follow-up of 7.8 years, no significant differences were observed in disease-free survival (adjusted hazard ratio 1.01, 95% confidence interval 0.74-1.37) or overall survival (hazard ratio 0.96, 95% confidence interval 0.62-1.50) between patients with ductal versus lobular tumors. No significant survival differences were observed according to specific BRCA gene, breast cancer subtype, or body mass index. CONCLUSIONS: In this large global cohort of young BRCA carriers with breast cancer, the incidence of pure lobular histology was low and associated with higher disease stage at diagnosis, luminal-like disease and BRCA2 PVs. Histology did not appear to impact prognosis.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Characteristics and clinical outcomes of breast cancer in young BRCA carriers according to tumor histology
- Date Crossref
- 01/10/2024
- Éditeur
- Elsevier BV
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Université Libre de Bruxelles Institut Jules Bordet pays non établi dans la noticeUniversité ou école supérieure
-
Institut Jules Bordet pays non établi dans la noticeÉtablissement de santé
-
Ospedale Policlinico San Martino pays non établi dans la noticeÉtablissement de santé
-
Université Paris Cité Department of Medical Oncology pays non établi dans la noticeUniversité ou école supérieure
-
Institut Curie pays non établi dans la noticeOrganisation à but non lucratif
-
Ulsan College Department of Surgery pays non établi dans la noticeUniversité ou école supérieure
-
Asan Medical Center pays non établi dans la noticeÉtablissement de santé
-
University of Ulsan pays non établi dans la noticeUniversité ou école supérieure
-
Inserm pays non établi dans la noticeOrganisme public
-
Institut Gustave Roussy pays non établi dans la noticeStructure de recherche
-
Sheba Medical Center The Danek Gertner Institute of Human Genetics pays non établi dans la noticeÉtablissement de santé
-
The Netherlands Cancer Institute pays non établi dans la noticeÉtablissement de santé
Institut Jules Bordet — Université Libre de Bruxelles, Institut Jules Bordet et Ospedale Policlinico San Martino, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.